Ascendis Pharma A/S (NASDAQ:ASND) Getting Somewhat Favorable Media Coverage, Accern Reports

News articles about Ascendis Pharma A/S (NASDAQ:ASND) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ascendis Pharma A/S earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.9290497558354 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Ascendis Pharma A/S (ASND) opened at 28.035 on Friday. Ascendis Pharma A/S has a 12-month low of $13.37 and a 12-month high of $31.86.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Tuesday, May 23rd. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by $0.19. The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $1.10 million. Ascendis Pharma A/S had a negative net margin of 1,944.88% and a negative return on equity of 58.53%. Equities analysts expect that Ascendis Pharma A/S will post ($3.42) earnings per share for the current fiscal year.

A number of equities research analysts recently issued reports on ASND shares. TheStreet downgraded shares of Ascendis Pharma A/S from a “c-” rating to a “d” rating in a research note on Thursday, June 15th. J P Morgan Chase & Co started coverage on shares of Ascendis Pharma A/S in a research note on Thursday, May 11th. They set an “overweight” rating and a $36.00 price target on the stock. Zacks Investment Research raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, May 24th. Wedbush reaffirmed an “outperform” rating and set a $34.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, April 3rd. Finally, ValuEngine upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Saturday, May 27th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Ascendis Pharma A/S presently has a consensus rating of “Buy” and an average target price of $29.60.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.